SynthesisThe Journal of international medical research2023
Prognostic impact of monocyte-to-lymphocyte ratio in coronary heart disease: a systematic review and meta-analysis.
Synthesis in The Journal of international medical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- The impact of platelet-to-lymphocyte ratio on clinical outcomes in heart failure: a systematic review and meta-analysis.Therapeutic advances in cardiovascular diseasePooled it
- Prognostic factors related to all-cause mortality in very long-term follow-up of patients with heart failure: the REMADHE trial extended analysis.BMC cardiovascular disorders · 2026Trial
- Value of different nutritional and inflammatory markers for diagnosis of peritonitis in patients undergoing peritoneal dialysis.Renal failure · 2026Article
- Associations of NLR, MLR, and (neutrophil + monocyte)/lymphocyte ratio with 30-day mortality in diabetic ICU patients with heart failure: A retrospective cohort study.International journal of cardiology. Heart & vasculature · 2026Article
- Age-Dependent Inflammatory, Lipid, and Echocardiographic Phenotypes in Acute Myocardial Infarction: Associations with In-Hospital Adverse Clinical Events.Biomedicines · 2026Article
- Tracking Lipoprotein(a) Risk Through Inflammatory Biomarkers.Acta Cardiologica Sinica · 2026Article
- Association between monocyte-to-lymphocyte ratio and mortality in critically ill patients with acute respiratory failure: a retrospective cohort study.Journal of thoracic disease · 2026Article
- Association of Complete Blood Count-Derived Inflammatory Markers with Trouble Sleeping: Evidence from Population Data and Experimental Sleep Deprivation.Nature and science of sleep · 2026Article
- Correlation of neutrophil/lymphocyte, monocyte/lymphocyte, and CRP/ALB ratios with the extent of coronary artery lesions and their predictive value.Frontiers in cardiovascular medicine · 2026Article
- Association between monocyte-to-lymphocyte ratio and metabolic dysfunction-associated steatotic liver disease and hepatic steatosis: evidence from NHANES 2017-2020.Translational gastroenterology and hepatology · 2026Article
- Monocyte-to-lymphocyte ratio as an inflammatory biomarker for predicting diabetic peripheral neuropathy in type 2 diabetes mellitus patients.BMC endocrine disorders · 2025Article
- Myeloid inflammation thresholds stratify mortality risk in early-stage cardiovascular-kidney-metabolic syndrome: MLR-driven findings from NHANES.Immunologic research · 2025Article
- Novel prognostic score based on the monocyte-to-lymphocyte ratio and CAVE score for epilepsy after primary intracerebral hemorrhage.BMC neurology · 2025Article
- Associations between the monocyte‑lymphocyte ratio and age‑related macular degeneration among US adults: evidence from NHANES 2005-2008.International journal of retina and vitreous · 2025Article
- The Monocyte-to-Lymphocyte Ratio Exhibits A Superior Prognostic Value in Patients with Newly Diagnosed Acute Coronary Syndrome.Reviews in cardiovascular medicine · 2025Article
- Identifying pathways to cardiovascular mortality by causal graphical models and mediation analysis among hypertensive patients: insights from a prospective study.Journal of translational medicine · 2025Article
- Association of the systemic immune-inflammatory index and systemic inflammatory response index with all-cause and cardiovascular mortality in individuals with metabolic inflammatory syndrome.European journal of medical research · 2025Article
- A Clinical Retrospective Study on the Combined Use of Monocyte-to-Lymphocyte Ratio and Triglyceride-Glucose Index to Predict the Severity of Coronary Artery Disease.Cardiology research · 2025Article
- Association between monocyte-to-lymphocyte ratio and cardiovascular diseases: insights from NHANES data.Diabetology & metabolic syndrome · 2025Article
- Plasma biomarkers for predicting heart failure in patients with acute myocardial infarction.Journal of medical biochemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveInflammatory biomarkers are novel tools to assess the prognosis of different cardiovascular diseases. We evaluated the impact of the monocyte-to-lymphocyte ratio (MLR) on clinical outcomes in patients with coronary heart disease (CHD).
methodsWe systematically screened English-language articles in PubMed, Scopus, and Web of Science to 31 August 2022. Relevant articles reporting the MLR and its association with clinical outcomes (major adverse cardiovascular events (MACE), coronary artery disease (CAD) severity, mortality, cardiac rupture, subclinical CAD, acute coronary syndrome (ACS) prediction, thin-cap fibroatheroma, no-reflow phenomenon, MLR-related differences in percutaneous coronary intervention, heart failure hospitalization, and depression) in patients with CHD were collected for further analysis.
resultsNineteen articles were selected. The mean MLR was 0.34. A higher MLR was significantly associated with an increased risk of MACE among patients with CHD. The MLR was an independent predictor of MACE in patients with ACS. No significant association was found for CAD severity. A complementary analysis was not performed because of few studies focusing on the other predefined endpoints.
conclusionsThe MLR is a simple and widely available tool to predict MACE in patients with CHD. This biomarker can be utilized in emergency settings to prioritize high-risk patients and optimize therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.